PSM INDIA brings together another memorable event for all healthcare stakeholders. Our 2nd International event at Radisson Blu Hotel, Haridwar from 6th-8th November,2014 primarily focuses on Patient Safety and Access to Quality Healthcare. On behalf of our Chairman, Mr. Wajahat Habibullah,IAS Retd., I cordially invite you all to our 11th Board meeting too on the 6th November 2014. Thank you all for registering for the event. We look forward to your presence. Incase you have not yet made your reservations with us, please go through this issue for further details on the event including the draft agenda. It would be an excellent platform to network and attend interesting and informative sessions throughout the conference. You may also visit our website jagograhakjago.com. for registration.
Read this issue to know more on the latest developments in the drug industry in India and globally. Learn more on Pharmacovigilance under our frequently asked questions section.
Mark your calendars for important upcoming events featured in this issue.
If you have any suggestions, comments or queries, please email me at pooja@jagograhakjago.com.
You may find our previous issues on our website jagograhakjago.com or in the NEWS ARCHIVE section of every issue of The PRESCRIPTION, in case you’ve missed any of them. You may also look us up on Facebook under Partnership for Safe Medicines India
"Call PSM India toll free helpline 1800 - 11- 4424, to bring cases of spurious medicines or any kind of adverse drug reaction to the notice of the authorities.
Please visit our website jagograhakjago.com if you wish to learn about us .
To register a complaint kindly visit our consumer redressal website jagograhakjago.com”
Happy Reading !
Stay Safe. Stay Healthy !
Pooja Khaitan
Chief Editor ,
The PRESCRIPTION
Partnership for Safe Medicines India.
“We have one of the strongest drug regulatory systems in the globe, which we keep on upgrading frequently whenever needed. Thus it is high time to clarify our stand and show the world that we are there to give world class services to one and all as patient safety is our top priority.”
Dr. H.G Koshia
Commissioner,
Food & Drugs Control Administration,
Gujarat State, India
Dallas nurse Nina Pham cleared of Ebola virus, released from hospitalOct, 2014: A Dallas-area nurse infected by the Ebola virus, and who sparked a nationwide search for other possible infections, was declared free of the virus and released from a Maryland hospital Friday.
Trio of Texans indicted for smuggling 100,000 fake pills into United StatesTexas, Oct 2014: 3 Texas residents are alleged to have received more than 30 shipments of fake medications and acted as drop-shippers for a drug counterfeiting operation run from China. Counterfeit versions of painkillers and lifestyle drugs were among the seized fakes.
US FDA approves Gilead's Harvoni to treat chronic hepatitis C genotype 1 infection
California, Oct 2014: The US Food and Drug Administration (US FDA) has approved Gilead Sciences' Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, approved under the trade name Sovaldi in December 2013. Harvoni's efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naïve patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL.
In today’s global environment, it doesn’t matter if you live in United States, Europe, Asia, India or Africa—everyone is at risk from unsafe drugs. Counterfeit drugs defraud consumers and deny patients therapies that can alleviate suffering and save lives. Unfortunately, in some cases, these drugs have caused great harm and fatalities.
But there are ways to minimize risk of getting a counterfeit medicine. The Partnership for Safe Medicines describes the various hidden poisons in form of counterfeit medication that consumers need to be aware of.
Frequently Asked Questions Q1. What is Pharmacovigilance?
Answer: Pharmacovigilance is the science and activities relating to the Detection, Assessment, Understanding and Prevention of adverse drug reactions or any other possible drug related problems. Generally speaking, pharmacovigilance is the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of drugs, biological products and traditional medicines with a view of identifying new information about hazards associated with medicines and preventing further harm to patients. The word pharmacovigilance has been derived from the Greek word pharmacon means ‘drug’ and the Latin word vigilare means ‘to keep awake or alert, to keep watch.’
Q2. What is the role of Pharmacovigilance Programme of India (PvPI)?
Answer: The mission of PvPI is to safeguard the health of the Indian population by ensuring that the benefit of use of medicine outweighs the risks associated with its use. The purpose of the PvPI is to collate data, analyze it and use the inferences to recommend informed regulatory interventions, besides communicating risks to healthcare professionals and the public and also detect and assess prescribing, dispensing and administration errors.
At present, Pharmacovigilance Programme of India is the main storehouse of suspected post-marketing adverse drug reactions in India. It ropes in medical colleges as Adverse drug reactions monitoring center (AMC). Once the Medical institute is enrolled as an AMC under PvPI, the AMC starts reporting ICSRs (Individual case safety reports) to NCC (National Coordinating center) via a VigiFlow software. These ICSRs are then assessed at NCC for quality of data and if found valid, they are further committed to the global drug monitoring center “Uppsala Monitoring Centre” in Sweden. PvPI aspires to expand the Pharmacovigilance programme to all hospitals (govt. & private) and centers of public health programs located across India, to develop and implement electronic reporting system (e-reporting) and to make ADR reporting mandatory for all healthcare professionals.
To read more visit at: http://www.ipc.gov.in/PvPI/pv_home.html